Drug profile · INN
luspatercept
REBLOZYL
luspatercept (REBLOZYL) is a transforming growth factor beta inhibitor.
EMA: approved Blood and blood forming organs (B03) B03XA06
Patents linked 0
Pipeline programs 7
News articles 0
Drug details — luspatercept
- Class
- Blood and blood forming organs (B03)
- Route
- —
- Patents
- 0
- Programs
- 7
- Data quality
- 0.83
Quick answer
luspatercept (REBLOZYL) is a transforming growth factor beta inhibitor.
Key facts
INN luspatercept
Brand REBLOZYL
Mechanism Transforming growth factor beta inhibitor
Target Transforming growth factor beta
Therapeutic class Blood and blood forming organs (B03)
ATC code B03XA06
Mechanism of action
Transforming growth factor beta inhibitor
Primary target: Transforming growth factor beta
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is luspatercept?
luspatercept (REBLOZYL) is a transforming growth factor beta inhibitor.
What is the brand name for luspatercept?
REBLOZYL is a marketed brand name for luspatercept. Check FDA Drugs@FDA for the current US label holder and prescribing information.